Analabs Resources Berhad Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Analabs Resources Berhad has been growing earnings at an average annual rate of 29.6%, while the Chemicals industry saw earnings growing at 6.5% annually. Revenues have been growing at an average rate of 7.3% per year. Analabs Resources Berhad's return on equity is 6.8%, and it has net margins of 20%.
Anahtar bilgiler
29.6%
Kazanç büyüme oranı
29.6%
EPS büyüme oranı
| Chemicals Sektör Büyümesi | 8.9% |
| Gelir büyüme oranı | 7.3% |
| Özkaynak getirisi | 6.8% |
| Net Marj | 20.0% |
| Son Kazanç Güncellemesi | 31 Jul 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?
Jan 04
Analabs Resources Berhad (KLSE:ANALABS) Is Due To Pay A Dividend Of MYR0.02
Feb 13Analabs Resources Berhad (KLSE:ANALABS) Is Doing The Right Things To Multiply Its Share Price
Mar 28Analabs Resources Berhad (KLSE:ANALABS) Has A Pretty Healthy Balance Sheet
Jan 21Here's Why Analabs Resources Berhad (KLSE:ANALABS) Can Manage Its Debt Responsibly
Sep 13Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?
May 24Analabs Resources Berhad (KLSE:ANALABS) Might Be Having Difficulty Using Its Capital Effectively
Apr 28Here's Why We Think Analabs Resources Berhad (KLSE:ANALABS) Is Well Worth Watching
Apr 07Could Analabs Resources Berhad (KLSE:ANALABS) Have The Makings Of Another Dividend Aristocrat?
Mar 17Should You Buy Analabs Resources Berhad (KLSE:ANALABS) For Its Upcoming Dividend?
Feb 19Does Analabs Resources Berhad (KLSE:ANALABS) Have A Healthy Balance Sheet?
Feb 09
Is Analabs Resources Berhad (KLSE:ANALABS) Set To Make A Turnaround?
Jan 14Is Analabs Resources Berhad (KLSE:ANALABS) An Attractive Dividend Stock?
Dec 07Gelir ve Gider Dağılımı
Analabs Resources Berhad nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Jul 24 | 146 | 29 | 11 | 0 |
| 30 Apr 24 | 152 | 28 | 11 | 0 |
| 31 Jan 24 | 158 | 35 | 7 | 0 |
| 31 Oct 23 | 154 | 33 | 7 | 0 |
| 31 Jul 23 | 145 | 31 | 10 | 0 |
| 30 Apr 23 | 133 | 28 | 11 | 0 |
| 31 Jan 23 | 125 | 12 | 18 | 0 |
| 31 Oct 22 | 123 | 21 | 18 | 0 |
| 31 Jul 22 | 116 | 23 | 15 | 0 |
| 30 Apr 22 | 116 | 29 | 14 | 0 |
| 31 Jan 22 | 120 | 29 | 13 | 0 |
| 31 Oct 21 | 119 | 24 | 12 | 0 |
| 31 Jul 21 | 117 | 19 | 12 | 0 |
| 30 Apr 21 | 117 | 16 | 13 | 0 |
| 31 Jan 21 | 108 | 13 | 14 | 0 |
| 31 Oct 20 | 105 | 9 | 14 | 0 |
| 31 Jul 20 | 109 | 9 | 14 | 0 |
| 30 Apr 20 | 111 | 7 | 15 | 0 |
| 31 Jan 20 | 109 | 5 | 15 | 0 |
| 31 Oct 19 | 112 | 5 | 16 | 0 |
| 31 Jul 19 | 122 | 5 | 16 | 0 |
| 30 Apr 19 | 130 | 4 | 17 | 0 |
| 31 Jan 19 | 136 | 8 | 4 | 0 |
| 31 Oct 18 | 142 | 10 | 8 | 0 |
| 31 Jul 18 | 136 | 9 | 12 | 0 |
| 30 Apr 18 | 138 | 9 | 17 | 0 |
| 31 Jan 18 | 145 | 9 | 14 | 0 |
| 31 Oct 17 | 144 | 9 | 15 | 0 |
| 31 Jul 17 | 148 | 11 | 17 | 0 |
| 30 Apr 17 | 150 | 11 | 19 | 0 |
| 31 Jan 17 | 158 | 12 | 22 | 0 |
| 31 Oct 16 | 155 | 13 | 23 | 0 |
| 31 Jul 16 | 158 | 14 | 24 | 0 |
| 30 Apr 16 | 155 | 13 | 24 | 0 |
| 31 Jan 16 | 151 | 12 | 24 | 0 |
| 31 Oct 15 | 153 | 9 | 26 | 0 |
| 31 Jul 15 | 143 | 7 | 23 | 0 |
| 30 Apr 15 | 142 | 7 | 23 | 0 |
| 31 Jan 15 | 135 | 6 | 51 | 0 |
| 31 Oct 14 | 136 | 8 | 38 | 0 |
| 31 Jul 14 | 140 | 8 | 28 | 0 |
| 30 Apr 14 | 140 | 10 | 18 | 0 |
| 31 Jan 14 | 146 | 11 | 18 | 0 |
Kaliteli Kazançlar: ANALABS has high quality earnings.
Büyüyen Kar Marjı: ANALABS's current net profit margins (20%) are lower than last year (21.3%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ANALABS's earnings have grown significantly by 29.6% per year over the past 5 years.
Büyüme Hızlandırma: ANALABS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: ANALABS had negative earnings growth (-4.9%) over the past year, making it difficult to compare to the Chemicals industry average (24.4%).
Özkaynak Getirisi
Yüksek ROE: ANALABS's Return on Equity (6.8%) is considered low.